Mylan N.V. (NASDAQ, TASE: MYL) today announced that it will host a conference call and live webcast, on Monday, Nov. 6, 2017, at 10:30 a.m. ET, to review the company's financial results for the...
Mylan N.V. (NASDAQ, TASE: MYL) today announced that the United States District Court for the Eastern District of Texas has issued a 135-page decision finding all asserted claims of the patents...
Mylan N.V. (NASDAQ, TASE: MYL) today announced that partner, Synthon, received marketing authorization approval in Europe for Glatiramer Acetate Injection 40 mg/mL, a therapeutically equivalent...
Mylan N.V. (NASDAQ, TASE: MYL) today announced the U.S. launch of Moxifloxacin Hydrochloride in 0.8% Sodium Chloride Injection, 400 mg/250 mL (1.6 mg/mL) in 250 mL single-dose flexible bags, the...
Mylan N.V. (NASDAQ, TASE: MYL) today confirmed that the company has launched in the U.S. the first Glatiramer Acetate Injection 40 mg/mL for 3-times-a-week injection that is an AP-rated...
Educational materials to help empower your customers.
What to know about our high quality generics.
Details about our brand name and generic medicines.
Resources that meet the specific needs of your institution.
Copyright © 2017 Mylan N.V. All Rights Reserved.
For U.S. Audiences Only
Please select one of our websites from the list below.
Mylan also is proud to do business in these locations.